AGP Executive Report
Last update: 39 minutes agoHepatitis B Trial: A revised study in Guinea-Bissau has received ethics approvals and could enroll 14,000 newborns, with half receiving the hepatitis B vaccine at birth and half waiting until six weeks. Babies whose mothers test positive for the virus would be excluded. The $1.6 million U.S.-funded trial remains contentious: the WHO recommends vaccination within 24 hours of birth to help prevent mother-to-child transmission, and reports say final government authorization is still pending.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.